CART-EGFR-IL13Ra2 cells

DRUG2 trials

Sponsors

University of Pennsylvania

Conditions

Glioblastoma

Phase 1

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

Active, not recruitingNCT05168423

University of PennsylvaniaGlioblastoma

Start: 2023-02-24End: 2039-12-19Updated: 2026-04-13

CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

Active, not recruitingNCT06973096

University of PennsylvaniaGlioblastoma

Start: 2025-07-18End: 2042-07-01Target: 9Updated: 2026-07-22

Related Papers

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

2026-06-15

Updated overall survival, safety, and neurologic function outcomes from a phase 1 trial of bivalent chimeric antigen receptor (CAR) T cell therapy in recurrent glioblastoma (GBM).

Journal of Clinical Oncology2026-05-27

Abstract 3444: Spatial profiling of recurrent glioblastoma in a Phase I clinical trial reveals favorable immune remodeling induced by intracerebroventricular CAR T therapy

Cancer Research2026-04-03

Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial.

2025-06-0124 citations

A phase 1 study of intracerebroventricular (ICV) delivery of bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2 in patients with recurrent glioblastoma (rGBM).

Journal of Clinical Oncology2025-05-284 citations

TMOD-02. PATIENT-DERIVED GLIOBLASTOMA ORGANOIDS AS REAL-TIME AVATARS FOR ASSESSING RESPONSES TO CLINICAL CAR-T CELL THERAPY

Neuro-Oncology2024-11-01

Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.

2024-03-13228 citations

CTIM-40. EARLY RADIOGRAPHIC RESPONSE AND ENGRAFTMENT OF PHASE I FIRST-IN-HUMAN BICISTRONIC CAR T CELLS CORRELATE WITH REAL-TIME AUTOLOGOUS GBM ORGANOID CYTOLYSIS

Neuro-Oncology2023-11-011 citations